What is the price target for PCSA stock?
7 analysts have analysed PCSA and the average price target is 25.5 USD. This implies a price increase of 820.58% is expected in the next year compared to the current price of 2.77.
PROCESSA PHARMACEUTICALS INC (PCSA) Forecast, Price Target & Analyst Ratings
NASDAQ:PCSA • US74275C4033
Current stock price
2.77 USD
+0.17 (+6.42%)
At close:
3 USD
+0.23 (+8.3%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PROCESSA PHARMACEUTICALS INC (PCSA).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$1.02
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$25.50
Upside
+ 820.58%
From current price of $2.77 to mean target of $25.50, Based on 7 analyst forecasts
Low
$25.25
Median
$25.50
High
$26.25
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for PCSA. The average price target is 25.5 USD. This implies a price increase of 820.58% is expected in the next year compared to the current price of 2.77.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
PCSA was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about PCSA.
In the previous month the buy percentage consensus was at a similar level.
PCSA was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-09-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-12-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-25 | HC Wainwright & Co. | Initiate | Buy |
| 2024-03-06 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2023-11-17 | Maxim Group | Downgrade | Buy -> Hold |
| 2023-04-04 | Benchmark | Maintains | Speculative Buy |
| 2023-04-03 | Oppenheimer | Maintains | Outperform |
| 2023-01-12 | Maxim Group | Maintains | Buy |
| 2022-04-19 | Maxim Group | Initiate | Buy |
| 2021-08-03 | Oppenheimer | Initiate | Outperform |
| 2021-08-02 | Oppenheimer | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$1.02
- Revenue Estimate
- N/A
- Revenue Q2Q
- N/A
- EPS Q2Q
- 86.40%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
PCSA is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -1.02 USD and the consensus revenue estimate is null USD.
Full Analyst Estimates 2026 - 2031
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 113.4K | 5K -95.59% | N/A -100.00% | N/A | N/A | 6.12M | -100.00% | |||||||||||
| EBITDA YoY % growth | -748.4K | -71.3K 90.47% | N/A -2,425.25% | N/A -113.06% | N/A 18.36% | N/A -79.87% | N/A -91.29% | N/A -80.67% | N/A 41.15% | N/A -5.18% | N/A -16.07% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -987.2K | -71.5K 92.76% | N/A -2,420.84% | N/A -147.79% | N/A 11.88% | -5.727M -63.56% | -11.732M -79.70% | -21.213M -75.13% | -11.387M 43.44% | -12.613M -5.19% | -14.074M -16.08% | -11.628M 16.87% | -12.175M -4.70% | -12.587M -3.38% | -11.238M 10.71% | -10.263M 8.68% | -10.568M -2.97% | |
| Operating Margin | -870.55% | -1,430.00% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -198.93% | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | -670.65 | -377.40 44.83% | -620.50 -68.92% | -216.75 65.32% | -103.28 55.13% | -10.97 81.42% | -3.83 78.83% | -5.36 -40.00% | 12.85 340.00% | 34.88 171.43% | 60.18 72.51% | 24.40 -59.46% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -1.02 86.40% | -1.02 83.68% | -1.02 41.71% | -0.77 70.23% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
39.44%
EPS Next 5 Year
39.75%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
PROCESSA PHARMACEUTICALS INC / PCSA Forecast FAQ
When does PROCESSA PHARMACEUTICALS INC (PCSA) report earnings?
PROCESSA PHARMACEUTICALS INC (PCSA) will report earnings on 2026-05-06.